TP53 and cancer: Given the clinical relevance of targeting CHK1 in p53-mediated cancers and our data demonstrating WT p53 regulates CHK1 and the CS-pathway, it became important to investigate whether p53 deficiency promotes deregulation of the CHK1-caspase-2 pathway.